Tier 3 — preclinical

17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex

Harrison DE, Strong R, Reifsnyder P, Kumar N, Fernandez E, Flurkey K, Javors MA, Lopez-Cruzan M, Macchiarini F, Nelson JF, Markewych A, Bitto A, Sindler AL, Cortopassi G, Kavanagh K, Kavanagh K, Leng L, Bucala R, Rosenthal N, Salmon A, Stearns TM, Bogue M, Miller RA
Aging cell 2021 20; 5; e13328

Bibliography

PubMed
PMID 33788371
PubMed Central
PMC8135004
DOI
10.1111/acel.13328
Funding
Funding/support listed in the publication: National Institute on Aging; NIH, National Cancer institute; U.S. Department of Health and Human Services > National Institutes of Health > National Institute on Aging.
Competing interests
The authors reported no competing interests.

Study snapshot

DesignPreclinical animal study with supporting assays as applicable
ModelGenetically heterogeneous mice
SampleMale and female genetically heterogeneous UM-HET3 mice
InterventionNR and other interventions tested in separate diet arms
DurationLifespan follow-up
EndpointsModel-specific physiological outcomes; Biochemical or functional measures reported in the study

What the study showed, in plain terms

NR did not significantly extend lifespan in either sex at the tested regimen in the Interventions Testing Program.

Key findings

NR did not significantly extend lifespan in either sex at the tested regimen in the Interventions Testing Program.

What this study can and cannot tell us

The title’s positive estradiol result belongs to a separate treatment arm. The NR null result is specific to the tested regimen and model.

Related papers in the corpus

Tier 4
Corrigendum to: 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex
et al. · Aging cell · 2022
Tier 3
NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang H et al. · Science (New York, N.Y.) · 2016

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology